ClinicalTrials.gg
CompletedNCT05465668Updated Jan 31, 2023

Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C

A Phase 1 interventional study of DWP16001 Drug A and DWP16001 Drug C in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWP16001 Drug A and DWP16001 Drug C in healty adult volunteers.

Read the detailed description

The study design is a Randomized, Open-label, Oral, Single-dose, Two-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUClast of DWP16001. Secondary endpoints were AUCinf, AUClast, Tmax, t1/2, CL/F, and Vd/F of DWP16001.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a body weight of ≥ 50.0 kg to ≤ 90.0 kg with a (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2

☞ BMI (kg/m2) = Body weight (kg) / {Height (m)}2

Exclusion criteria

Exclusion Criteria:

  • musculoskeletal diseases
  • mental diseases
  • hemato-oncologic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Intervention: DWP16001 Drug A

    1 tablet, Oral, once daily single dose

    Drug: DWP16001 Drug A

  • Experimental
    Intervention: DWP16001 Drug C

    1 tablet, Oral, once daily single dose

    Drug: DWP16001 Drug C

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss of DWP16001

    Peak Plasma Concetration of DWP16001

    Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.

  2. AUClast of DWP16001

    The area under the plasma drug concentration-time curve of DWP16001

    Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.

Secondary outcomes

  1. Tmax of DWP16001

    Time at Cmax of DWP16001

    Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.

  2. T1/2 of DWP16001

    Half life of DWP16001

    Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.

  3. CL/F of DWP16001

    Apparent total clearance of the drug from plasma after oral administration of DWP16001

    Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.

  4. Vd/F of DWP16001

    Volume of distribution of DWP16001

    Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.

07

Study locations

1 site
  • CHA unuversity bundang medical center
    Seongnam, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Aug 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 20, 2022
StartActual
Jul 22, 2022
Primary completionActual
Aug 16, 2022
CompletionActual
Nov 22, 2022
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05465668
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jul 22, 2022
Primary completion
Aug 16, 2022
Completion
Nov 22, 2022
Last update
Jan 31, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion